Not necessarily about infectious disease, but still of possible interest:
European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Company's empagliflozin*, an investigational type 2 diabetes treatment (NYSE:LLY)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.